NASDAQ: INDP
Indaptus Therapeutics Inc Stock Ownership - Who owns Indaptus Therapeutics?

Insider buying vs selling

Have Indaptus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jeffrey A. MecklerChief Executive Officer2025-07-276,068$8.30
$50.38kBuy
Jeffrey A. MecklerCEO and Director2024-11-2542,553$1.18
$50.00kBuy

1 of 1

INDP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when INDP insiders and whales buy or sell their stock.

INDP Shareholders

What type of owners hold Indaptus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Dexcel Pharma Technologies Ltd382.72%4,234,897$27.53MInsider
Michael James Newman123.66%1,368,356$8.89MInsider
Glen R. Anderson117.87%1,304,318$8.48MInsider
John W. Kozarich13.72%151,761$986.45kInsider
Anthony J. Maddaluna4.84%53,570$348.21kInsider
Nadav Navon1.76%19,456$126.46kInsider
Jeffrey A. Meckler1.20%13,312$86.53kInsider
Gil Bianco0.90%10,000$65.00kInsider
Issac Silberman0.36%4,000$26.00kInsider
Boyan Vesselinov Litchev0.10%1,150$7.48kInsider

1 of 2

INDP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INDP0.00%100.00%Net BuyingNet Buying
IBO3.87%17.31%Net Selling
ALZN0.01%99.99%Net BuyingNet Buying
ACXP50.37%49.63%Net Buying
CANF0.02%0.00%

Indaptus Therapeutics Stock Ownership FAQ

Who owns Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ: INDP) is owned by 0.03% institutional shareholders, 647.16% Indaptus Therapeutics insiders, and 0.00% retail investors. Dexcel Pharma Technologies Ltd is the largest individual Indaptus Therapeutics shareholder, owning 4.23M shares representing 382.72% of the company. Dexcel Pharma Technologies Ltd's Indaptus Therapeutics shares are currently valued at $27.53M.

If you're new to stock investing, here's how to buy Indaptus Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.